Breakthrough in Platinum-Resistant Ovarian Cancer Treatment: Relacorilant Meets Key Survival Goal in Phase 3 Trial

Spread the Message

Read Time:4 Minute, 9 Second

Corcept Therapeutics announced on January 22, 2026, that its experimental drug relacorilant, combined with nab-paclitaxel chemotherapy, met the primary endpoint of improved overall survival in the phase 3 ROSELLA trial for patients with platinum-resistant ovarian cancer. This development offers hope for a hard-to-treat cancer subtype affecting thousands of women globally, where treatment options are limited. The results build on earlier data showing benefits in progression-free survival, positioning relacorilant for potential regulatory approval.

Trial Key Findings

The ROSELLA trial enrolled 381 patients with platinum-resistant ovarian cancer, randomizing them 1:1 to receive relacorilant plus nab-paclitaxel or nab-paclitaxel alone. The combination reduced the risk of death by 35% (hazard ratio 0.65, p=0.0004), extending median overall survival to 16.0 months versus 11.9 months in the control arm—a 4.1-month gain. Earlier interim results had confirmed a 30% reduction in progression-free survival risk, with both dual primary endpoints now met.

Safety profiles were comparable between arms, with no increase in adverse events’ type, frequency, or severity from adding relacorilant. The clinical benefit rate reached 51.1% in the combination group versus 38.9% in monotherapy (p=0.016). These outcomes held across subgroups, including those previously treated with PARP inhibitors, without biomarker restrictions.

Drug Mechanism and Background

Relacorilant is an oral selective glucocorticoid receptor antagonist that blocks cortisol-mediated signaling in tumors, countering chemotherapy resistance without disrupting systemic hormone balance. Glucocorticoids like cortisol can activate pro-survival pathways in ovarian cancer cells, enhancing DNA repair and anti-apoptotic effects, which contribute to platinum resistance. By targeting these receptors selectively, relacorilant spares progesterone and mineralocorticoid pathways, allowing continuous dosing with minimal added toxicity.

Platinum-resistant ovarian cancer develops when disease recurs within six months of platinum-based therapy, affecting about 25% of patients initially and most upon recurrence. Ovarian cancer ranks as the third most common among women in India (47,333 cases, 32,978 deaths in 2022) and causes around 12,740 U.S. deaths yearly. Median progression-free survival in this group is typically 9-12 months, underscoring the unmet need.

Expert Perspectives

Alexander Olawaiye, MD, principal investigator and director of gynecological cancer research at Magee-Women’s Hospital, University of Pittsburgh, stated: “The addition of relacorilant to nab-paclitaxel is positioned to become a new standard-of-care treatment for patients with platinum-resistant ovarian cancer, due to its overall survival benefit, well-tolerated side effect profile and oral administration.” Domenica Lorusso, MD, PhD, from Humanitas University, added that the results “demonstrate that relacorilant in combination with nab-paclitaxel has the potential to become a key strategy to help improve patient outcomes.”

Independent experts echo this optimism. The trial’s design, including blinded independent central review for progression-free survival, strengthens credibility, per publications in The Lancet and ASCO presentations. Corcept’s Chief Development Officer Bill Guyer noted plans for regulatory filings in the U.S. (PDUFA date July 11, 2026) and Europe.

Public Health Implications

If approved, relacorilant could extend life for women with few options beyond weekly nab-paclitaxel, bevacizumab, or biomarker-limited therapies like mirvetuximab soravtansine. Its oral format and lack of biomarker requirement broaden access, especially in resource-constrained settings like India where BRCA testing is unaffordable for many (92.8% in one cohort). This addresses a global burden: platinum resistance halves median survival compared to sensitive disease.

Patients might gain months of quality life, delaying further progression. Corcept plans phase 2 trials in endometrial, cervical, pancreatic, and prostate cancers, expanding cortisol modulation’s role. Stock surges post-announcement reflect market confidence in commercialization.

Limitations and Balanced View

While promising, ROSELLA focused on platinum-resistant cases, not earlier stages or primary resistance (15-21% incidence). Long-term data beyond median survival and real-world effectiveness remain unproven. No new safety signals emerged, but monitoring for glucocorticoid-related effects continues.

Conflicting viewpoints note glucocorticoids’ routine anti-nausea use in oncology; relacorilant’s antagonism warrants careful patient selection. Alternatives like PARP inhibitors succeed in BRCA-mutated subsets but fail broadly in resistant disease. Regulatory hurdles persist, with FDA review ongoing. Ongoing trials like BELLA (with bevacizumab) will clarify broader utility.

Practical Advice for Readers

Women with ovarian cancer should discuss relacorilant with oncologists once approved, especially if platinum-resistant. It complements nab-paclitaxel, a standard weekly infusion. Track symptoms like abdominal pain or bloating, and prioritize clinical trials via sites like ClinicalTrials.gov (NCT05257408). Lifestyle factors—balanced diet, exercise—support treatment but do not replace it. Early detection via CA-125 monitoring aids outcomes.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.